Latest news with #InspireMedicalSystems
Yahoo
3 days ago
- Business
- Yahoo
Piper Sandler Lowers PT on Inspire Medical Systems (INSP) to $150 From $233
Inspire Medical Systems, Inc. (NYSE:INSP) is one of the top NYSE stocks with the highest upside potential. Piper Sandler lowered the firm's price target on Inspire Medical Systems, Inc. (NYSE:INSP) to $150 from $233 on August 5, keeping an Overweight rating on the shares. A medical professional performing a minimally invasive procedure while using the company's technology. The rating update came after the company's quarterly results, with the firm stating that while Inspire Medical Systems, Inc. (NYSE:INSP) reported better-than-feared fiscal Q2 2025 results, the focus of the EPS call was on the company's revised FY2025 guidance. The guidance was considerably lowered to take into account a number of headwinds, a majority of which are associated with the Gen 5 rollout. The firm added that while it had suspected that it could see a downward revision, it was disappointed by the magnitude of the cut to both the top and bottom-line guide. Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company that develops and commercializes innovative, minimally invasive solutions for obstructive sleep apnea. The company offers Inspire therapy, which includes implantable components with a pressure-sensing lead, a stimulation lead, and a neurostimulator, operable through a remote control. While we acknowledge the potential of INSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
4 days ago
- Business
- Yahoo
Robert W. Baird Remains a Buy on Inspire Medical Systems (INSP)
Inspire Medical Systems, Inc. (NYSE:INSP) is one of the top oversold NYSE stocks to buy now. Robert W. Baird analyst David Rescott maintained a Buy rating on Inspire Medical Systems, Inc. (NYSE:INSP) on August 5, setting a price target of $150.00. A medical professional performing a minimally invasive procedure while using the company's technology. The rating update came after Inspire Medical Systems, Inc.'s (NYSE:INSP) release of its fiscal Q2 2025 earnings on August 4. Inspire Medical Systems, Inc. (NYSE:INSP) generated $217.1 million in revenue in fiscal Q2 2025, reflecting an 11% rise over the same quarter last year. Gross margin for the quarter reached 84.0%, while net loss was $3.6 million. The company reported $13.3 million in adjusted net income, while adjusted diluted earnings per share were $0.45 for fiscal Q2 2025. Inspire Medical Systems, Inc. (NYSE:INSP) also announced the initiation of the full launch of the Inspire V neurostimulation system in the United States. Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company that develops and commercializes innovative, minimally invasive solutions for obstructive sleep apnea. The company offers Inspire therapy, which includes implantable components with a pressure-sensing lead, a stimulation lead, and a neurostimulator, operable through a remote control. While we acknowledge the potential of INSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
4 days ago
- Business
- Yahoo
Unpacking Q1 Earnings: Haemonetics (NYSE:HAE) In The Context Of Other Medical Devices & Supplies
Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and worst performers in the medical devices & supplies - specialty industry. The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies, although specialty devices are more niche. The capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers. The 7 medical devices & supplies - specialty stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 0.9%. While some medical devices & supplies - specialty stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 3.2% since the latest earnings results. Haemonetics (NYSE:HAE) With roots dating back to 1971 and a mission to improve blood-related healthcare, Haemonetics (NYSE:HAE) provides specialized medical devices and software for blood collection, processing, and management across plasma centers, blood banks, and hospitals. Haemonetics reported revenues of $330.6 million, down 3.7% year on year. This print exceeded analysts' expectations by 1%. Overall, it was a satisfactory quarter for the company with an impressive beat of analysts' organic revenue estimates. Interestingly, the stock is up 20.7% since reporting and currently trades at $77.52. Is now the time to buy Haemonetics? Access our full analysis of the earnings results here, it's free. Best Q1: Inspire Medical Systems (NYSE:INSP) Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE:INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep. Inspire Medical Systems reported revenues of $201.3 million, up 22.7% year on year, outperforming analysts' expectations by 3.1%. The business had a very strong quarter with an impressive beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates. Inspire Medical Systems delivered the fastest revenue growth among its peers. Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 15.5% since reporting. It currently trades at $134.45. Is now the time to buy Inspire Medical Systems? Access our full analysis of the earnings results here, it's free. Weakest Q1: Globus Medical (NYSE:GMED) With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures. Globus Medical reported revenues of $598.1 million, down 1.4% year on year, falling short of analysts' expectations by 4.7%. It was a softer quarter as it posted a significant miss of analysts' full-year EPS guidance estimates. Globus Medical delivered the highest full-year guidance raise but had the weakest performance against analyst estimates in the group. As expected, the stock is down 21.5% since the results and currently trades at $56.84. Read our full analysis of Globus Medical's results here. STAAR Surgical (NASDAQ:STAA) With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ:STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens. STAAR Surgical reported revenues of $42.59 million, down 44.9% year on year. This number beat analysts' expectations by 5.5%. It was a strong quarter as it also produced an impressive beat of analysts' constant currency revenue estimates. STAAR Surgical delivered the biggest analyst estimates beat but had the slowest revenue growth among its peers. The stock is down 12.5% since reporting and currently trades at $17. Read our full, actionable report on STAAR Surgical here, it's free. Integer Holdings (NYSE:ITGR) With its name reflecting the mathematical term for "whole" or "complete," Integer Holdings (NYSE:ITGR) is a medical device outsource manufacturer that produces components and systems for cardiac, vascular, neurological, and other medical applications. Integer Holdings reported revenues of $437.4 million, up 7.3% year on year. This result surpassed analysts' expectations by 2%. It was a strong quarter as it also recorded a solid beat of analysts' full-year EPS guidance and organic revenue estimates. The stock is flat since reporting and currently trades at $120.47. Read our full, actionable report on Integer Holdings here, it's free. Market Update The Fed's interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump's presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Inspire Medical (INSP) Takes 32% Nosedive on Dismal Earnings, Outlook
We recently published . Inspire Medical Systems, Inc. (NYSE:INSP) is one of the worst-performing stocks on Tuesday. Inspire Medical nosedived by 32.35 percent on Tuesday to end at $87.91 apiece as investors unloaded portfolios following a disappointing earnings performance in the second quarter of the year, coupled with a lower growth outlook for the full year. This followed the company's swing to a $3.59 million net loss in the second quarter of the year, reversing a $9.8 million net income in the same period last year. Revenues, however, jumped by 10.7 percent to $217 million from $195.88 million in the same comparable period. In the first half, Inspire Medical Systems, Inc. (NYSE:INSP) said it widened its net loss by 183 percent to $600 million from $212 million, while revenues grew by 16 percent to $418 million from $360 million. Commenting on the company's performance, Inspire Medical Systems, Inc. (NYSE:INSP) Chairman and CEO Tim Herbert believed that operational headwinds were just temporary and that actions are underway to address them. Copyright: lenetstan / 123RF Stock Photo For full-year 2025, the company expects revenues to now settle between $900 million and $910 million, lower than the $940 million to $955 million expected previously. While we acknowledge the potential of INSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
5 days ago
- Business
- Business Insider
Inspire Medical Systems Stock (INSP) Dives After Reporting a Q2 Beat & Guidance Cut
Inspire Medical Systems (INSP) stock plummeted on Tuesday following the release of the medical technology company's Q2 2025 earnings report. This started with adjusted earnings per share of 45 cents, compared to Wall Street's estimate of 20 cents. The company's adjusted EPS also increased 40.63% year-over-year from 32 cents. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inspire Medical Systems reported revenue of $217.1 million in Q2, which surpassed analysts' estimate of $214.49 million. It was also up 11% from the $195.88 million reported in the second quarter of 2024. This was fueled by the launch of its Inspire V system in the U.S. However, investors' hopes were hurt when Inspire Medical Systems Chairman and CEO Tim Herbert noted that 'the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.' Inspire Medical Systems Guidance Inspire Medical Systems lowered its 2025 guidance in its latest earnings report. It now expects revenue for the year to range from $900 million to $910 million, compared to its previous estimate of $940 to $955 million. This would also see it miss Wall Street's 2025 revenue estimate of $914.74 million. Inspire Medical Systems stock was down 30.48% in pre-market trading on Tuesday, following a 3.05% rally yesterday. The shares have also decreased 29.9% year-to-date and 11.6% over the past 12 months. The guidance cut announced by Inspire Medical Systems has already resulted in several lowered price targets, including UBS analyst Danielle Antalffy cutting her price target for INSP shares to $230 from $270. Is Inspire Medical Systems Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Inspire Medical Systems is Strong Buy, based on 10 Buy and three Hold ratings over the past 12 months. With that comes an average INSP stock price target of $210.09, representing a potential 61.67% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today's earnings report.
